Header Logo

Connection

ULRICH STRYCH to Humans

Back to Details
This is a "connection" page, showing publications ULRICH STRYCH has written about Humans.
ULRICH STRYCH
Connection Strength
0.274
Humans
  1. Generation and Characterization of In Vitro Transcribed mRNA. Methods Mol Biol. 2024; 2786:147-165.
    View in: PubMed
    Score: 0.024
  2. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv Drug Deliv Rev. 2021 03; 170:71-82.
    View in: PubMed
    Score: 0.020
  3. New Vaccines for the World's Poorest People. Annu Rev Med. 2016; 67:405-17.
    View in: PubMed
    Score: 0.014
  4. Characteristic profiling of CHO-cell expressed MERS-CoV RBD-Fc. Int J Biol Macromol. 2025 Jun; 311(Pt 2):143678.
    View in: PubMed
    Score: 0.007
  5. Mechanistic insights into the structure-based design of a CspZ-targeting Lyme disease vaccine. Nat Commun. 2025 Apr 07; 16(1):2898.
    View in: PubMed
    Score: 0.007
  6. Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization. Front Immunol. 2024; 15:1480976.
    View in: PubMed
    Score: 0.006
  7. Optimization of Cellular Transduction by the HIV-Based Pseudovirus Platform with Pan-Coronavirus Spike Proteins. Viruses. 2024 09 20; 16(9).
    View in: PubMed
    Score: 0.006
  8. What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective? J Infect Dis. 2024 Aug 16; 230(2):382-393.
    View in: PubMed
    Score: 0.006
  9. The zebrafish as a potential model for vaccine and adjuvant development. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):535-545.
    View in: PubMed
    Score: 0.006
  10. Biophysical and biochemical characterization of a recombinant Lyme disease vaccine antigen, CspZ-YA. Int J Biol Macromol. 2024 Feb; 259(Pt 2):129295.
    View in: PubMed
    Score: 0.006
  11. From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):495-500.
    View in: PubMed
    Score: 0.006
  12. Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights. Expert Rev Vaccines. 2022 10; 21(10):1405-1417.
    View in: PubMed
    Score: 0.005
  13. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. Vaccine. 2022 06 09; 40(26):3655-3663.
    View in: PubMed
    Score: 0.005
  14. Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study. Lancet Public Health. 2022 04; 7(4):e356-e365.
    View in: PubMed
    Score: 0.005
  15. An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Sci Transl Med. 2022 Jan 26; 14(629):eabj5305.
    View in: PubMed
    Score: 0.005
  16. Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. Protein Expr Purif. 2022 02; 190:106003.
    View in: PubMed
    Score: 0.005
  17. Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination. J Infect Dis. 2021 09 17; 224(6):938-948.
    View in: PubMed
    Score: 0.005
  18. Identification of vaccine targets in pathogens and design of a vaccine using computational approaches. Sci Rep. 2021 09 02; 11(1):17626.
    View in: PubMed
    Score: 0.005
  19. A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. Sci Immunol. 2021 07 15; 6(61).
    View in: PubMed
    Score: 0.005
  20. Facing the challenges of multidrug-resistant Acinetobacter baumannii: progress and prospects in the vaccine development. Hum Vaccin Immunother. 2021 10 03; 17(10):3784-3794.
    View in: PubMed
    Score: 0.005
  21. Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1. Appl Microbiol Biotechnol. 2021 May; 105(10):4153-4165.
    View in: PubMed
    Score: 0.005
  22. SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Hum Vaccin Immunother. 2021 08 03; 17(8):2356-2366.
    View in: PubMed
    Score: 0.005
  23. The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine. Am J Prev Med. 2021 05; 60(5):605-613.
    View in: PubMed
    Score: 0.005
  24. Correlates and disparities of intention to vaccinate against COVID-19. Soc Sci Med. 2021 03; 272:113638.
    View in: PubMed
    Score: 0.005
  25. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020 11 03; 38(47):7533-7541.
    View in: PubMed
    Score: 0.005
  26. A scalable and reproducible manufacturing process for Phlebotomus papatasi salivary protein PpSP15, a vaccine candidate for leishmaniasis. Protein Expr Purif. 2021 01; 177:105750.
    View in: PubMed
    Score: 0.005
  27. Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. Am J Prev Med. 2020 10; 59(4):493-503.
    View in: PubMed
    Score: 0.005
  28. COVID-19 vaccines: neutralizing antibodies and the alum advantage. Nat Rev Immunol. 2020 07; 20(7):399-400.
    View in: PubMed
    Score: 0.005
  29. Coronavirus vaccine-associated lung immunopathology-what is the significance? Microbes Infect. 2020 10; 22(9):403-404.
    View in: PubMed
    Score: 0.005
  30. The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission. Vaccine. 2020 04 03; 38(16):3261-3270.
    View in: PubMed
    Score: 0.005
  31. Protective immunity elicited by the nematode-conserved As37 recombinant protein against Ascaris suum infection. PLoS Negl Trop Dis. 2020 02; 14(2):e0008057.
    View in: PubMed
    Score: 0.005
  32. Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. Vaccine. 2019 06 19; 37(28):3704-3714.
    View in: PubMed
    Score: 0.004
  33. Covalent vaccination with Trypanosoma cruzi Tc24 induces catalytic antibody production. Parasite Immunol. 2018 Nov; 40(11):e12585.
    View in: PubMed
    Score: 0.004
  34. Characterization and Stability of Trypanosoma cruzi 24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease. J Pharm Sci. 2018 05; 107(5):1468-1473.
    View in: PubMed
    Score: 0.004
  35. Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate. J Pharm Sci. 2017 08; 106(8):1961-1970.
    View in: PubMed
    Score: 0.004
  36. A simple fluorescence-based assay for quantification of the Toll-Like Receptor agonist E6020 in vaccine formulations. Vaccine. 2017 03 07; 35(10):1410-1416.
    View in: PubMed
    Score: 0.004
  37. Human anthelminthic vaccines: Rationale and challenges. Vaccine. 2016 06 24; 34(30):3549-55.
    View in: PubMed
    Score: 0.004
  38. Advancing a vaccine to prevent hookworm disease and anemia. Vaccine. 2016 06 03; 34(26):3001-3005.
    View in: PubMed
    Score: 0.004
  39. Advancing a vaccine to prevent human schistosomiasis. Vaccine. 2016 06 03; 34(26):2988-2991.
    View in: PubMed
    Score: 0.004
  40. Status of vaccine research and development of vaccines for Chagas disease. Vaccine. 2016 06 03; 34(26):2996-3000.
    View in: PubMed
    Score: 0.004
  41. Status of vaccine research and development of vaccines for leishmaniasis. Vaccine. 2016 06 03; 34(26):2992-2995.
    View in: PubMed
    Score: 0.004
  42. Sensitive detection of norovirus using phage nanoparticle reporters in lateral-flow assay. PLoS One. 2015; 10(5):e0126571.
    View in: PubMed
    Score: 0.003
  43. Neglected tropical diseases among the Association of Southeast Asian Nations (ASEAN): overview and update. PLoS Negl Trop Dis. 2015 Apr; 9(4):e0003575.
    View in: PubMed
    Score: 0.003
  44. Label-free, in situ SERS monitoring of individual DNA hybridization in microfluidics. Nanoscale. 2014 Aug 07; 6(15):8521-6.
    View in: PubMed
    Score: 0.003
  45. Ultrasensitive immuno-detection using viral nanoparticles with modular assembly using genetically-directed biotinylation. Biotechnol Lett. 2014 Sep; 36(9):1863-8.
    View in: PubMed
    Score: 0.003
  46. Functionalized viral nanoparticles as ultrasensitive reporters in lateral-flow assays. Analyst. 2013 Oct 07; 138(19):5584-7.
    View in: PubMed
    Score: 0.003
  47. Biophysical characterization of VEGF-aHt DNA aptamer interactions. Int J Biol Macromol. 2013 Jun; 57:69-75.
    View in: PubMed
    Score: 0.003
  48. Recovery of small DNA fragments from serum using compaction precipitation. PLoS One. 2012; 7(12):e51863.
    View in: PubMed
    Score: 0.003
  49. New classes of alanine racemase inhibitors identified by high-throughput screening show antimicrobial activity against Mycobacterium tuberculosis. PLoS One. 2011; 6(5):e20374.
    View in: PubMed
    Score: 0.003
  50. The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design. BMC Microbiol. 2011 May 25; 11:116.
    View in: PubMed
    Score: 0.003
  51. Engineered 5S ribosomal RNAs displaying aptamers recognizing vascular endothelial growth factor and malachite green. J Mol Recognit. 2009 Mar-Apr; 22(2):154-61.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.